Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 18/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 18/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587824 | 1.00 | PIM1 (0.42) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL15589002 | 0.87 | PIM1 (0.36) | PIM1PIM3PIM2 | |
| SCHEMBL16588146 | 0.87 | PIM1 (0.36) | PIM1PIM3PIM2 | |
| SCHEMBL16587825 | 0.80 | PIM1 (0.42) | PIM1PIM3PIM2 | |
| SCHEMBL16587827 | 0.80 | PIM2 (0.49) | PIM1PIM3PIM2 | |
| SCHEMBL16587817 | 0.79 | PIM1 (0.42) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL16587821 | 0.79 | PIM1 (0.42) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL16587794 | 0.78 | PIM1 (0.39) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL16587792 | 0.78 | PIM1 (0.39) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL16587819 | 0.78 | PIM2 (0.49) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.